Potassium dobesilate topical - DermAct Pharmaceutical

Drug Profile

Potassium dobesilate topical - DermAct Pharmaceutical

Alternative Names: AM-001

Latest Information Update: 11 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator DermAct Pharmaceutical
  • Developer AmDerma Pharmaceuticals; DermAct Pharmaceutical
  • Class Benzenesulfonates; Potassium compounds; Skin disorder therapies; Small molecules
  • Mechanism of Action Fibroblast growth factor inhibitors; Fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Actinic keratosis; Plaque psoriasis

Most Recent Events

  • 12 Jun 2017 Phase-II clinical trials in Actinic keratosis in USA (Topical) (NCT03210740)
  • 23 Jan 2017 Chemical structure information added
  • 02 Jan 2017 No development reported - Phase-II for Plaque psoriasis in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top